Eiger BioPharmaceuticals
Eiger BioPharmaceuticals was a Palo Alto-based biopharmaceutical company developing rare-disease therapeutics, notably Zokinvy (FDA-approved for HGPS) and avexitide (Phase 3-ready for post-bariatric hypoglycemia), both of which were divested to larger pharmaceutical firms in 2024.
- Company typePrivate
- Founded2008
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Eiger BioPharmaceuticals firmographics
Firmographics- Name
- Eiger BioPharmaceuticals
- Website
- https://eigerbio.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Unknown
- Headcount range
- 11–50 employees
- Short description
- Eiger BioPharmaceuticals was a Palo Alto-based biopharmaceutical company developing rare-disease therapeutics, notably Zokinvy (FDA-approved for HGPS) and avexitide (Phase 3-ready for post-bariatric hypoglycemia), both of which were divested to larger pharmaceutical firms in 2024.
- Ownership category
- akta.pro rank
Eiger BioPharmaceuticals industry classification
Industry- Product category
- Specialty Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
Keywords
Where Eiger BioPharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Markets served
Eiger BioPharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- Asset Licensing/Sale: Eiger BioPharmaceuticals generates revenue through licensing and selling drug assets to other pharmaceutical companies. In 2024, the company sold avexitide (GLP-1 receptor antagonist) to Amylyx Pharmaceuticals and Zokinvy (lonafarnib) to Sentynl Therapeutics.
- Debt Financing: Eiger raised capital through term loan agreements and stock purchase agreements with financial partners to support pipeline development.
Eiger BioPharmaceuticals product offering
Product offeringCore offering
Eiger BioPharmaceuticals is a clinical-stage biopharmaceutical company that develops and commercializes therapies for rare diseases and antiviral indications. The company's core commercial and pipeline assets include Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Avexitide for post-bariatric hypoglycemia. The company sells pharmaceutical products through specialty distribution channels to treat patients with ultra-rare and rare conditions.
Product overview
Eiger BioPharmaceuticals is a biopharmaceutical company that has developed treatments for rare diseases. The company has sold key products including Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and avexitide for post-bariatric hypoglycemia. Based on available source data, the company's current product portfolio following these divestitures is not specified in the provided sources.
Differentiator
Problem solved
Functional benefit
Products and services
- Zokinvy (lonafarnib) An oral farnesyltransferase inhibitor approved by the FDA for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) and processing-deficient progeroid laminopathies in patients 12 months of age and older. Sold to specialty pharmacies and prescribers treating ultra-rare pediatric aging disorders.
- Avexitide An investigational glucagon-like peptide-1 (GLP-1) receptor antagonist being developed for the treatment of post-bariatric hypoglycemia (PBH), a rare metabolic complication following bariatric surgery. Targeted at specialty endocrinology and bariatric medicine practices.
Quantifiable outcome
- PBH affects approximately 160,000 people in the U.S. with no current treatments available
- +1 more outcomes
Companies that use Eiger BioPharmaceuticals
Customer profileSegments2 records
Ideal customer profiles2 records
Eiger BioPharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Eiger BioPharmaceuticals partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Amylyx PharmaceuticalscoreAmylyx Pharmaceuticals acquired avexitide (GLP-1 receptor antagonist) from Eiger BioPharmaceuticals in July 2024 for post-bariatric hypoglycemia (PBH). Amylyx is advancing the asset through pivotal Phase 3 LUCIDITY trial with topline results expected in Q3 2025/Q3 2026 and potential NDA submission and 2026/2027 launch.
- Sentynl TherapeuticscoreSentynl Therapeutics acquired Zokinvy (lonafarnib) from Eiger BioPharmaceuticals in May 2024, a strategic move to address unmet medical needs of patients with ultra-rare genetic conditions like Hutchinson-Gilford Progeria Syndrome (HGPS).
Scale indicators4 records
Recent moves4 records
Expansion highlights2 records
Eiger BioPharmaceuticals competitors and assessment
Company assessmentDirect peers
- Ultragenyx Pharmaceutical: Clinical-stage biopharmaceutical company focused exclusively on rare and ultra-rare genetic diseases, with multiple FDA-approved therapies. Directly comparable to Eiger in rare-disease pipeline focus, regulatory strategy, and small/mid-cap biotech profile.
- BioMarin Pharmaceutical: Established rare-disease biopharmaceutical company developing therapies for ultra-rare conditions, several of which were first-in-class. Comparable to Eiger in targeting small patient populations with high unmet need and using regulatory pathways like orphan drug designation.
- Alexion Pharmaceuticals (AstraZeneca Rare Disease): Specialty biopharmaceutical company focused on rare diseases including complement-mediated conditions. Highly comparable to Eiger's positioning in ultra-rare diseases with first-in-class approvals and a similar developer-to-commercializer evolution.
- Arrowhead Pharmaceuticals: Clinical-stage biopharmaceutical company developing RNAi-based therapies, with hepatitis B as a lead program. Closely comparable to Eiger's hepatitis D antiviral focus, leveraging novel modalities against infectious liver disease.
- Assembly Biosciences: Clinical-stage biopharmaceutical company developing antivirals for hepatitis B and hepatitis D. Direct therapeutic-area overlap with Eiger's hepatitis D franchise and similar small-cap infectious-disease developer profile.
- Vir Biotechnology: Clinical-stage immunology company developing therapeutics for serious infectious diseases including hepatitis B. Comparable to Eiger as an infectious-disease-focused small/mid-cap biotech pursuing antiviral therapies.
- Soleno Therapeutics: Clinical-stage biopharmaceutical company developing therapies for rare diseases, with a focus on ultra-rare genetic conditions. Comparable to Eiger in size, rare-disease strategy, and small-cap clinical-stage profile.
Emerging players
- Madrigal Pharmaceuticals: Biopharmaceutical company developing therapies for liver diseases including NASH. Adjacent peer to Eiger given shared focus on liver-related indications and small-cap specialty pharma profile.
- Intercept Pharmaceuticals: Specialty biopharmaceutical company historically focused on chronic liver diseases including NASH and primary biliary cholangitis. Adjacent peer to Eiger given shared liver-disease focus and small-cap biopharma profile.
Broad incumbents
- Recordati Rare Diseases: Established specialty pharmaceutical group with a dedicated rare-disease business unit marketing therapies across multiple ultra-rare indications. Comparable to Eiger's commercial strategy for Zokinvy in HGPS-type ultra-rare conditions.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat2 records
Key risks1 record
Key highlights5 records
Customer concentration
Eiger BioPharmaceuticals social profiles
Digital presenceEiger BioPharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eiger BioPharmaceuticals leadership team
Management profileNumber of profiles
Profiles3 records
Eiger BioPharmaceuticals funding detail
Funding detailFunding overview
Funding rounds9 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eiger BioPharmaceuticals M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eiger BioPharmaceuticals
What does Eiger BioPharmaceuticals do?
Eiger BioPharmaceuticals is a clinical-stage biopharmaceutical company that develops and commercializes therapies for rare diseases and antiviral indications. The company's core commercial and pipeline assets include Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Avexitide for post-bariatric hypoglycemia. The company sells pharmaceutical products through specialty distribution channels to treat patients with ultra-rare and rare conditions.
When was Eiger BioPharmaceuticals founded?
Eiger BioPharmaceuticals was founded in 2008. It employs 11 to 50 people.
Where is Eiger BioPharmaceuticals based?
Eiger BioPharmaceuticals is headquartered in Palo Alto, United States, in the North America region.
How does Eiger BioPharmaceuticals make money?
Two revenue lines are on record. Asset Licensing/Sale is the primary driver. The others are debt Financing.
Who are Eiger BioPharmaceuticals's main competitors?
Direct peers on record are Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Arrowhead Pharmaceuticals, Assembly Biosciences, Vir Biotechnology and Soleno Therapeutics. Emerging players are Madrigal Pharmaceuticals and Intercept Pharmaceuticals. Recordati Rare Diseases is listed as a broad incumbent.
Does Eiger BioPharmaceuticals have an API?
No public API is recorded for Eiger BioPharmaceuticals.
What industry is Eiger BioPharmaceuticals in?
Eiger BioPharmaceuticals's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 325414 and its SIC code is 2836.